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Screen-detected breast cancer patients show a better survival than
breast cancer patients who are detected outside a screening
programme (Wolfe, 1991; Harris and Vogel, 1997; Schroën et al,
1998). According to the early results of the Dutch trial in
Nijmegen the breast cancer mortality rate in women of 35 and over
can be reduced by roughly 50% by regular mammographic
screening of all eligible women (Verbeek et al, 1984). Other
studies have shown similar results (Tabàr, 1985; Peeters et al,
1998). This is mainly explained by early detection of screen-
detected tumours. It may, however, be possible that factors other
than tumour size are responsible for better survival figures.
Screen-detected cancers may be less aggressive than non-screen-
detected cancers.
One way to determine tumour aggressiveness is to measure the
mitotic activity index (MAI). The MAI is an index made out of the
mitotic frequency in the most active part of the tumour, and there-
fore is a quantitative feature of the tumour. In recent literature
quantitative factors, such as the MAI, are good prognostic factors
for patient survival (Baak, 1985; Baak et al, 1985; van der Linden
et al, 1986, 1987, 1989; Theissig et al, 1996; Uyterlinde et al,
1987, 1990; Aaltomaa et al, 1991; van Diest et al, 1992). They
discriminate very well less aggressive tumours from more aggres-
sive ones. Measuring the MAI is easily learned and can be
performed in a highly reproducible way if a strict protocol is care-
fully followed (van Diest et al, 1992; Jannink et al, 1995; Collan et
al, 1996).
The aim of this study was to investigate whether there is a
difference in the MAI between screen and non-screen detected
breast cancers, and to evaluate the prognostic value of the MAI for
recurrence free survival, adjusting for other prognostic factors.
MATERIALS AND METHODS
A retrospective evaluation was performed of 387 evaluable
patients with breast cancer who were treated between January
1992 and September 1997. The median period of follow up was
2.6 years (range 0.2–6.2). Ninety patients with a mean age of 58
years (range 48–72 years), had screen-detected breast cancer,
while 297 patients with a mean age of 54 years (range 28–93
years), had non-screen-detected breast cancer. Breast cancer
screening was usually performed in the age group 50–70 years.
Patients were surgically treated with a modified radical mastec-
tomy (n = 305, 79%) or a breast saving procedure (n = 82, 21%).
Radiotherapy was used in breast saving procedures (21%) and in
case of T3/T4 tumours or chest-wall contamination (11%).
Adjuvant irradiation of the axilla was used when there was extra-
nodal involvement (15%). Radiotherapy was used in screen- and
non-screen-detected patients in the same frequency. Use of
adjuvant chemotherapy was depending on lymph node involve-
ment and menopausal status. Chemotherapy was given as CMF
(cyclophosphamide, 100 mg m–2 orally on days 1–14;
methotrexate, 40 mg m–2 intravenously on days 1 and 8; and 
fluorouracil, 600 mg m–2 intravenously on days 1 and 8) in 105
patients (27%). Use of adjuvant chemotherapy was not different
for screen- or non-screen-detected patients. Hormone treatment in
the form of adjuvant tamoxifen 20 mg day–1 for a period of 5 years
was given to 79 patients (20%), according to receptor status,
menopausal status and lymph node status. Use of hormone treat-
ment was equal over groups of screen- and non-screen-detected
patients. Tumour size, histological type, differentiation grade,
hormone receptor status and lymph node involvement were deter-
mined by the pathologist. Grading of the invasive carcinoma was
carried out according to the Elston method described in Diagnostic
Histopathology of the Breast by Page and Anderson (Elston,
1987). The method involves the assessment of three components
of tumour morphology: tubule formation, nuclear pleomorphism
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great majority of the tumour was composed of formed tubules.
When tubule formation was seen in moderate amounts, a score of
2 points was made. Where little or no tubule formation was seen,
the score was given as 3 points. For nuclear pleomorphism a score
of 1, 2, or 3 was given if the tumour cells showed little, moderate
or strong variation in shape and size of the nuclei respectively. The
mitotic rate was assessed by counting the number of mitoses in ten
high-power fields. Fewer than ten mitoses were given 1 point,
10–19 mitoses were given 2 points, and 20 mitoses or more were
given 3 points. Adding the three scores together gave the histolog-
ical grade of differentiation. Tumours were considered well differ-
entiated (grade I) if the total score was 3–5 points (n = 76, 19%),
moderately differentiated (grade II) with a score of 6–7 points (n =
157, 40%), and poorly differentiated (grade III) if the score was
8–9 points (n = 161, 41%). The MAI was assessed in the subjec-
tively most cellular and proliferative area of the tumour, usually at
the periphery of the tumour, avoiding regions of necrosis and
inflammation. The mitosis counting was performed using a Leitz
microscope at ´400 magnification (´10 ocular and ´40 objective
with a numerical aperture of 0.70 and a field diameter of 525 mm).
The MAI was determined by counting the mitoses in ten consecu-
tive high-power fields (Jannink et al, 1995).
Statistical methods
Differences in geometric means of the MAI between groups were
tested for significance after logarithmic transformation of the
MAI. This was performed with a one-way analysis or a t-test
depending on the number of groups. The difference in MAI
between screen-detected and non-screen-detected cancers was
adjusted for other tumour characteristics, i.e. tumour size, lymph
node involvement, lymph vessel invasion, blood vessel invasion
and hormone receptor status by multiple regression analysis.
Recurrence-free actuarial survival curves were computed for
tumours with MAI from 1 to 9, 10–24 and above 24. The relation
between the MAI and recurrence free survival was adjusted for
other tumour characteristics and detection mode by a proportional
hazards model. A significance level of 0.05 was used.
RESULTS
In patients who were not screen-detected (n = 297), there was no
difference in the MAI between 148 patients younger than 50 years
and 149 patients of 50 years or older.
Because the patients in the non-screen-detected group were
younger, the non-screen-detected group was matched for age with
the screen-detected group by selecting all patients from 50 to 70
years old. We chose this group because in the screening group the
majority of patients were between 50 and 70 years (82/90). After
adjusting for age 176 of 387 screen- and non-screen-detected
patients remained between 50 and 70 years old. The patient char-
acteristics of these groups are given in Table 1. In this group the
ratio of the geometric means of the MAI in the non-screen-
detected versus screen-detected remained 2.0 (confidence interval
(CI) 1.4–2.8, P < 0.0001). The geometric mean of the MAI in the
screen-detected group was half the geometric mean of the non-
screen-detected group (6 vs 12, P < 0.0001), even after stratifica-
tion for T and N stages. Only in N1 patients from 50 to 70 years
was the MAI not significantly different (Table 2).
The MAI correlated well with other important tumour factors,
such as histological type, lymph vessel invasion, blood vessel
invasion, tumour size and lymph node involvement, and receptor
status (Table 3).
After adjustment for mode of detection, tumour stage (T),
lymph node involvement (N), lymph vessel invasion, blood vessel
invasion and hormone recptor status in a multivariate analysis, the
MAI remained a strong independent prognostic factor for recur-
rence of disease. The risk ratio for recurrence of disease after
adjustment for all variables in a multivariate analysis was 1.01 
(P < 0.04).
After adjustment for T, N, lymph vessel invasion, and blood
vessel invasion in a multivariate analysis of all patients between
50 and 70 years, the ratio of the geometric means of the MAI was
1.7 (CI 1.2–2.4, P < 0.0004).
After adjustment for hormone receptor status, the ratio was 1.4
(CI 0.95–1.9, P < 0.09), indicating that even after correction for
these prognostic factors, the MAI is higher in the non-screen
detected than in the screen detected patients with breast cancer.
382 RPR Groenendijk et al
British Journal of Cancer (2000) 82(2), 381–384 © 2000 Cancer Research Campaign
Table 1 Patient characteristics of 176 patients between 50 and 70 years
Screen-detected Non-screen-detected
Number 82 94
Mean age 58 (50–70) 58 (50–70) NS
Follow-up (years) 2.7 (0.3–5.9) 2.7 (0.3–5.9) NS
MAI (median) 6 12 P < 0.001
Tumour status
T1 51/82 35/94
T2 27/82 38/94
T3 1/82 9/94
T4 3/82 12/94
N0 56/82 38/94
N1 24/82 48/94
N2 2/82 3/94
Unknown 0/82 5/94
Mastectomy 55/82 77/94 NS
Adjuvant treatment
Chemotherapy 11/82 18/94 NS
Hormone therapy 18/82 25/94 NS
Radiotherapy 32/82 50/94 NS
NS, not significant.
Table 2 MAI for screen- and non-screen-detected cancers, stratified for T
and N stages, all patients between 50 and 70 years
MAI P-value
geometric mean (P25-P75)
Screen-detected Non-screen-detected
Overall 6 (3–16) 12 (6–29) < 0.0001
(all ages) n = 90 n = 297
Tumour size
T1 6(3–15) 12(6–36) = 0.004
n = 51 n = 35
T2 6(2–19) 14(6–27) = 0.03
n = 27 n = 38
Nodal status
N0 5(2–13) 11(5–23) = 0.0009
n = 56 n = 38
N1 9(5–20) 12(6–29) = 0.28 (NS)
n = 24 n = 48
NS, not significant; n, number of tumours.The 5-year recurrence-free survival was 90% in the screen-
detected group, versus 67% in the other group. Also the MAI was
a significant univariate prognostic factor for recurrence-free
survival (Figure 1).
DISCUSSION
Screening for breast cancer is an effective method to detect breast
cancer in an early stage of disease. Clinical breast examination and
mammography are recommended as combined modalities for
breast cancer screening (Freund et al, 1998). The use of supple-
mental ultrasound has been advocated in patients with radio-
graphically dense breasts, but there appears to be no significant
contribution to the accuracy of the work-up (Maestro et al, 1998).
In The Netherlands the screening programme has been introduced
in the whole country for women between 50 and 70 years old
(Fracheboud et al, 1998). Population survey in younger women
seems to be less beneficial (Smart, 1992; Elwood et al, 1993; Peer
et al, 1996; Harris and Vogel, 1997). Recently the age for
screening in The Netherlands has been increased up to 75 years,
because a reduction in breast cancer mortality due to mammo-
graphic screening has been shown for women aged up to 75 years
(van Dijck et al, 1997a, 1997b). A breast cancer screening
programme leads to an increased use of breast conserving therapy
and an increased need for post-operative radiotherapy; there will
also be a higher number of women diagnosed with non-invasive
breast cancer (Borras et al, 1998). As we have shown both in this
study and before (Schroën et al, 1996), the screen-detected
tumours were more often in an earlier stage than the tumours
detected outside the screening programme. The recurrence-free
survival in patients with tumours detected in the screening
programme, was significantly better compared to patients with
tumours detected outside the screening programme. The finding
that the MAI was low in the screen-detected group supports the
idea that screen-detected tumours are generally more favourable
than others, because they are growing more slowly and are
detected with mammography earlier for that reason. We consid-
ered only the MAI and not other factors that contribute to differen-
tiation grade of the tumour. The length time bias caused by this
phenomenon has always been a point of controversy in uncon-
trolled breast screening projects. Our study makes clear that this
bias is certainly not only of theoretical importance. That the low
MAI is found not only in T1 tumours, but also in T2 indicates that
T2 tumours detected outside the screening programmes are of a
different biological behaviour. The large size of the tumour is per
se not a prognostic factor but the MAI of it is.
The MAI itself is an important prognostic factor for recurrence
free survival. We were able to corroborate other studies that the
MAI correlates well to other prognostic factors. The prognostic
importance is even better when the MAI is used in other scoring
systems, such as the multivariate prognostic index (MPI), which
combines the MAI, lymph node status and tumour size (van der
Linden et al, 1987). We found that the MAI alone is an important
predictor for disease-free survival.
The MAI is a factor that can attribute to predicting poor respon-
ders to chemotherapy (van Diest et al, 1992). Others suggested that
the decisions on adjuvant therapy in breast cancer can be based on
the MAI and the MPI, particularly in node-negative patients (Baak
et al, 1989, 1993; Aaltomaa et al, 1993). Assessing morphometric
features of a resected specimen of breast cancer should be incorpo-
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Figure 1 Recurrence-free survival for tumours with a MAI from 1–9, 10–24,
and above 24. Log rank test: P<0.0001.
Table 3 Relation of the MAI with other prognostic factors
Factors n MAI P-value
geometric mean
Histological type
Ductal 272 13
Lobular 53 4
Tubular 12 1
Medullar 6 45
Mixed type 36 8 0.001
Rest 8
Lymph vessel invasion
Positive 195 7
Negative 190 16 <0.001
Blood vessel-invasion
Positive 24 20
Negative 361 10 0.007
T-stage
T1 153 8
T2 145 12
T3 33 15
T4 51 13 0.005
N-stage (nodal status)
N0 180 8
N1 187 13
N2 7 20 <0.001
Oestrogen receptor status
Positive 25 9
Negative 82 18 <0.001
Progesterone receptor status
Positive 26 9
Negative 100 20 0.002rated in routine pathology reports (van der Linden et al, 1987;
Baak et al, 1992). Regional differences in prognosis of breast
cancer are correlated with the MAI and other microscopic features
(Baak et al, 1992). According to Jannink et al (1995) counting the
MAI as we described before gives the strongest prognostic value.
Collan et al give an efficient description of the method and its reli-
ability (Collan et al, 1996). It takes about 10–15 min extra time to
calculate the MAI in a tumour. It can be learned within a reason-
able time to perform mitosis counting in a highly reproducible
manner in a routine setting. However, motivation and on-going
quality control are essential to guarantee the reproducibility of the
assessments (van Diest et al, 1992; Uyterlinde et al, 1995).
As far as we know there is no previous study investigating the
MAI in relation to the mode of detection of breast cancer. Tumours
detected by screening have a significant lower MAI than tumours
detected outside the screening programme. This implies that these
tumours have a different profile, even when they have the same
stage of disease. Besides the fact that screen detected tumours are
detected earlier, they are also equipped with a favourable MAI,
thus leading to a better prognosis.
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